BioSpace News Archive

Carrick Therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2- advanced breast cancer and samuraciclib for the treatment of locally advanced or metastatic triple negative breast cancer.

Castellum, Inc. (OTC: ONOV) announces that it has acquired Specialty Systems, Inc. (SSI) a Toms River, New Jersey based government contractor.

Myungsung C&M, a Korean orthodontic product manufacturer, has recently released its new product, which is A+ Expander as MARPE that Myungsung C&M introduces.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today initiation of preparation for filing an Emergency Use Authorization (EUA) to the FDA for JadiCells™ in treatment of COVID-19 associated lung injury.

Enveda Biosciences today announced two key hires to accelerate its translational drug development efforts. It follows the closing of an oversubscribed $51M Series A financing round in June.

Aerin Medical Inc., a company dedicated to providing Ear Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced that the American Journal of Rhinology & Allergy has published positive one-year results from a trial evaluating the safety and efficacy of RhinAer® in patients with chronic rhinitis

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of individuals with BMD.

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2021, as well as key clinical and corporate developments.

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first patient has been enrolled in the Phase 1/2 study evaluating the safety and tolerability of mRNA-3705, its investigational mRNA therapeutic for methylmalonic acidemia (MMA), administered via intravenous infusion in patients with isolated MMA due to MUT deficiency.

Technicolor Precision BioDevices (TPB), a member of the creative technology leader Technicolor (Euronext Paris: TCH, OTCQX: TCLRY), announces a collaboration with Scope Fluidics to manufacture cartridges for their BacterOMIC system.